Advocacy group seeks withdrawal of Victoza

04/19/2012 | Atlanta Journal-Constitution, The

Consumer watchdog Public Citizen is calling on the FDA to withdraw Novo Nordisk's diabetes drug Victoza in light of clinical reviews linking the drug to an increased risk of kidney failure, thyroid cancer and pancreatitis. "In the two years since Victoza was approved, Novo Nordisk has continued to work closely with the FDA and the medical community to monitor the benefits and appropriate use [of the drug]," the Danish company said. "Our experience in those two years does not support the Public Citizen call to deprive patients of the benefits of Victoza."

View Full Article in:

Atlanta Journal-Constitution, The

Published in Briefs: